Futures Mixed Ahead...
Health Care: Drugs
Actavis Inc (ACT: NYSE)
$124.62 -1.05 | -0.84%
06/19/13 - 12:31 PM ET
Company Balance Sheet
| Dec 2012 | Dec 2011 | Dec 2010 | Dec 2009 | |
| Assets | ||||
|---|---|---|---|---|
| Cash and Equivalents | 319.00M | 209.30M | 282.80M | 201.40M |
| Receivables | 1.30B | 1.17B | 560.90M | 519.50M |
| Inventories | 1.54B | 889.40M | 631.00M | 692.30M |
| Other Current Assets | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Current Assets | 3.88B | 2.57B | 1.80B | 1.77B |
| Property, Plant & Equipment, Gross | 2.23B | 1.41B | 1.27B | 1.20B |
| Accumulated Depreciation & Depletion | 745.50M | 693.80M | 623.30M | 503.20M |
| Property, Plant & Equipment, Net | 1.48B | 713.70M | 642.30M | 695.50M |
| Intangibles | 3.83B | 1.61B | 1.63B | 1.72B |
| Other Non-Current Assets | 91.20M | 71.30M | 84.50M | 114.50M |
| Total Non-Current Assets | 10.22B | 4.13B | 4.03B | 4.22B |
| Liabilities & Shareholder Equity | ||||
| Total Assets | 14.10B | 6.70B | 5.83B | 5.99B |
| Accounts Payable | 684.80M | 875.80M | 250.70M | 615.20M |
| Short Term Debt | 176.20M | 184.50M | 0.00 | 307.60M |
| Other Current Liabilities | 68.40M | 106.70M | 39.90M | 78.40M |
| Total Current Liabilities | 2.71B | 1.84B | 820.70M | 1.05B |
| Long Term Debt | 6.26B | 848.50M | 1.02B | 1.15B |
| Deferred Income Taxes | 1.04B | 279.10M | 441.50M | 615.90M |
| Other Non-Current Liabilities | 244.20M | 168.70M | 266.40M | 150.60M |
| Minority Interest | 1.00M | -1.80M | -1.10M | 0.00 |
| Total Non-Current Liabilities | 7.56B | 1.30B | 1.72B | 1.92B |
| Total Liabilities | 10.27B | 3.13B | 2.55B | 2.97B |
| Preferred Stock Equity | 0.00 | 0.00 | 0.00 | 0.00 |
| Common Stock Equity | 3.83B | 3.56B | 3.28B | 3.02B |
| Common Par | 400.00K | 400.00K | 400.00K | 400.00K |
| Additional Paid In Capital | 1.96B | 1.88B | 1.77B | 1.69B |
| Cumulative Translation Adjustment | 0.00 | 0.00 | 0.00 | 0.00 |
| Retained Earnings | 2.18B | 2.09B | 1.82B | 1.64B |
| Treasury Stock | -342.80M | -326.70M | -312.50M | -306.20M |
| Other Equity Adjustments | 36.80M | -76.50M | -2.50M | 1.90M |
| Total Capitalization | 10.09B | 4.41B | 4.30B | 4.17B |
| Total Equity | 3.83B | 3.56B | 3.28B | 3.02B |
| Total Liabilities & Stock Equity | 14.10B | 6.70B | 5.83B | 5.99B |
| Total Common Shares Outstanding | 127.70M | 127.20M | 125.80M | 123.40M |
| Preferred Shares | 0.00 | 0.00 | 0.00 | 0.00 |
| Treasury Shares | 10.30M | 10.00M | 9.70M | 9.60M |
| Basic Weighted Shares Outstanding | 125.80M | 124.50M | 122.40M | 105.00M |
| Diluted Weighted Shares Outstanding | 128.40M | 126.50M | 124.20M | 116.40M |
| Number of Employees | 17700 | 6686 | 6030 | 5830 |
| Number of Part-Time Employees | 0 | 0 | 0 | 0 |
Portfolios with ACT
- Portfolio NameUser Type
- ContributorHigh Volume Technicals for ...
- ContributorHigh Volume Technicals for ...
Latest ACT Headlines from TheStreet
- Quick Take: Fund Manager All-In On Actavis, Visa 06.18.13 | 01:06 pm
- Go All-In On Actavis, Visa
06.18.13 | 11:06 am - Cramer's Top Stock Picks: RRGB BLMN GCI OPK CCO ACT BGS 06.18.13 | 06:06 am
- Cramer's 'Mad Money' Recap: Don't Fear the Fed 06.17.13 | 08:06 pm
- NVO, NVS And ACT, Pushing Drugs Industry Downward 05.28.13 | 01:05 pm
- Actavis Inc (ACT): Today's Featured Health Care Laggard 05.23.13 | 05:05 pm
- The Deal: Actavis Extends Gains Following Warner Deal 05.21.13 | 03:05 pm
- Stocks Slip on Concerns Markets Overpriced 05.20.13 | 04:05 pm
- Ireland Welcomes Watson Pharmaceuticals, an American Success 05.20.13 | 02:05 pm
- The Deal: Actavis Plays Hunter in $8.5 Billion Deal for Ireland's Warner Chilcott 05.20.13 | 10:05 am
Press Releases for ACT
- Actavis Confirms Generic Safyral® Patent Challenge - PR Newswire 06.05.13 | 04:06 pm
- Actavis To Acquire Warner Chilcott To Create Premier $11 Billion Revenue Global Specialty Pharmaceutical Company - PR Newswire 05.20.13 | 07:05 am
- Announcement Under Irish Takeover Rules Relevant Securities In Issue - PR Newswire 05.14.13 | 01:05 am
- Actavis Acquires Worldwide Rights For Valeant's Metronidazole 1.3% Vaginal Gel - PR Newswire 05.01.13 | 08:05 am
- Actavis Acquires Worldwide Rights For Valeant's Metronidazole 1.3% Vaginal Gel - PR Newswire 05.01.13 | 08:05 am
- Actavis Reaches Agreement With Shire To Launch A Generic Version Of Intuniv® In December 2014 - PR Newswire 04.25.13 | 09:04 am
- Actavis Reaches Agreements With Valeant To Launch Generic Versions Of Ziana® And Zyclara® - PR Newswire 04.10.13 | 08:04 am
- Actavis Reaches Agreements With Valeant To Launch Generic Versions Of Ziana® And Zyclara® - PR Newswire 04.10.13 | 08:04 am
- Actavis And Valeant Announce Actavis As Exclusive Authorized Generic Marketer Of Zovirax® Ointment; Co-Promotion Agreements On Zovirax® Cream And Cordran® Tape - PR Newswire 04.05.13 | 08:04 am
- Actavis And Valeant Announce Actavis As Exclusive Authorized Generic Marketer Of Zovirax® Ointment; Co-Promotion Agreements On Zovirax® Cream And Cordran® Tape - PR Newswire 04.05.13 | 08:04 am
Partner Headlines for ACT
- 5 Stocks To Watch For Gains Next Week - Seeking Alpha 06.07.13 | 07:06 pm
- CRL for Endo Health's Aveed - Analyst Blog - Zacks 06.04.13 | 12:06 am
- CVR Energy, Warner Chilcott and Other Top Performers in May - Benzinga 06.02.13 | 09:06 am
- Stocks Up 1% In Afternoon; PolyOne Retakes Buy Point - Investor's Business Daily 05.28.13 | 01:05 pm
- Stock Market News for May 21, 2013 - Market News - Zacks 05.21.13 | 03:05 pm
- UPDATE: Piper Jaffray Raises PT on Actavis on Pro Forma Estimates - Benzinga 05.21.13 | 01:05 pm
- Actavis, Warner Chilcott Stocks Rise On Merger News - Investor's Business Daily 05.20.13 | 06:05 pm
- Actavis to acquire Warner Chilcott in $5bn pharmaceutical deal - Financial Times 05.20.13 | 03:05 pm
- Dealmaking fails to send Wall St higher - Financial Times 05.20.13 | 02:05 pm
- Stocks Hold Mild Gains; Small-Cap Ambarella Breaks Out - Investor's Business Daily 05.20.13 | 01:05 pm
